Technology in Cancer Research & Treatment (Mar 2023)

Ablative Therapies for Breast Cancer: State of Art

  • Serena Carriero MD,
  • Carolina Lanza MD,
  • Giuseppe Pellegrino MD,
  • Velio Ascenti MD,
  • Caterina Sattin MD,
  • Caterina Pizzi MD,
  • Salvatore Alessio Angileri MD,
  • Pierpaolo Biondetti MD, PhD,
  • Andrea Antonio Ianniello MD,
  • Filippo Piacentino MD,
  • Roberto Lavorato MD,
  • Anna Maria Ierardi MD,
  • Gianpaolo Carrafiello MD

DOI
https://doi.org/10.1177/15330338231157193
Journal volume & issue
Vol. 22

Abstract

Read online

Breast cancer (BC) is the most frequently diagnosed malignancy among women. In the past two decades, new technologies and BC screening have led to the diagnosis of smaller and earlier-stage BC (ESBC). Therefore, percutaneous minimally invasive techniques (PMIT) were adopted to treat patients unfit for surgery, women who refuse it, or elderly patients with comorbidities that could make surgery a difficult and life-threatening treatment. The target of PMIT is small-size ESBC with the scope of obtaining similar efficacy as surgery. Minimally invasive treatments are convenient alternatives with promising effectiveness, lower morbidity, less cost, less scarring and pain, and more satisfying cosmetic results. Ablative techniques used in BC are cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound (US), and laser ablation. The aim of our study is to discuss the current status of percutaneous management of BC, evaluate the clinical outcomes of PMIT in BC, and analyze future perspectives regarding ablation therapy in BC.